RadNet and Hologic partner on AI tools development for breast health

7 August 2020 (Last Updated August 7th, 2020 16:20)

Imaging services provider RadNet and diagnostic products developer Hologic have agreed to collaborate on developing artificial intelligence (AI) tools for breast health.

RadNet and Hologic partner on AI tools development for breast health
RadNet and Hologic have agreed to partner on breast health AI. Credit: Gerd Altmann / Pixabay.

Imaging services provider RadNet and diagnostic products developer Hologic have agreed to collaborate on developing artificial intelligence (AI) tools for breast health.

According to the agreement, the two companies will share data and upgrade RadNet’s existing fleet of Hologic mammography systems to include Hologic’s 3DQuorum and Genius 3D imaging technology.

According to the companies, the collaboration will be supported by RadNet’s recent purchase of DeepHealth, a company that uses machine learning (ML) to develop software tools for cancer detection.

Hologic Breast and Skeletal Health Solutions Division president Pete Valenti said: “We believe the future of breast health will rely heavily on the integration of AI tools such as our 3DQuorum imaging technology, as well as next-generation CAD software that aid in the early detection of breast cancer.”

“We are energised by the opportunities this transformative collaboration with RadNet creates for patients and clinicians alike. Access to data is critical in training and refining AI algorithms.

“With this collaboration, we now have the opportunity to leverage data from the largest fleet of high-resolution mammography systems to develop new tools across the continuum of care, provide workflow efficiencies and improve patient satisfaction and outcomes.”

Furthermore, all of the Hologic systems of RadNet are expected to feature the Genius 3D Mammography exam.

Genius 3D Mammography is the only mammogram that is clinically proven and Food and Drug Administration (FDA) approved as superior for all women compared to 2D mammography. 

In May, Hologic received emergency use authorisation (EUA) from the US FDA for the Aptima SARS-CoV-2 assay.

In June 2019, Hologic signed an exclusive negotiation agreement to acquire France-based cart-based ultrasound products innovator SuperSonic Imagine.